What Elevian does

Elevian is a privately held, clinical-stage biotechnology company developing recombinant protein therapeutics based on Growth Differentiation Factor 11 (GDF11), a circulating blood factor that declines with age. Founded in 2018 by Harvard Stem Cell Institute scientists (Lee Rubin, Amy Wagers, Rich Lee, Ryan Walker) alongside serial biotech entrepreneurs Mark Allen (CEO) and Sebastian Giwa (Chairman), the company is headquartered in Allston, Massachusetts. Its lead program, rGDF11, is a recombinant protein shown in preclinical models to facilitate motor function recovery in both ischemic and hemorrhagic stroke by promoting neovascularization, neurogenesis, and reducing inflammation, with a therapeutic window extending into hours-to-days post-stroke, in contrast to existing neuroprotective therapies that must be administered within the first few hours.

The company's broader pipeline leverages rGDF11 and additional GDF11 pathway modulators to address cardiovascular, metabolic (obesity, Type II diabetes), pulmonary, renal, inflammatory, and skeletal muscle dysfunction. Elevian has secured exclusive worldwide rights to a portfolio of granted patents covering GDF11 polypeptide compositions and their therapeutic uses, and has developed a scalable, high-producing rGDF11 cell line and purification process for IND-enabling and early clinical studies. The company is pre-revenue with no commercial products; its business model is the standard clinical-stage biotech path of advancing therapeutics through regulatory approval and ultimately to pharmaceutical product sales or licensing partnerships, supported by clinical trial site engagement with hospitals and rehabilitation centers.

Name

Elevian

Legal name

Elevian, Inc.

Website

https://elevian.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Elevian is a clinical-stage biotech developing recombinant GDF11 (rGDF11) protein therapeutics, with a lead program targeting stroke recovery and a broader pipeline for age-related diseases including cardiovascular, metabolic, and neuromuscular disorders.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industries

Neural & Spinal Cord Regeneration (HLAAAGAI), Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

Keywords

• Regenerative medicine therapeutics
• Stroke recovery treatment
• Recombinant protein drugs
• Anti-aging biotechnology
• Age-related disease therapies

Headquarters

HQ city

Allston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Therapeutics: As a pre-revenue biotech company, Elevian does not currently generate revenue. The company is developing rGDF11 and GDF11 pathway modulators as therapeutic candidates targeting stroke recovery and age-related diseases. Future revenue will come from pharmaceutical product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Elevian develops a pipeline of regenerative medicines centered on recombinant Growth Differentiation Factor 11 (rGDF11), a protein therapeutic that has demonstrated in preclinical models the ability to promote recovery from stroke and treat age-related diseases. The lead program targets post-stroke recovery by promoting neovascularization, neurogenesis, and reducing inflammation. Additional programs utilize rGDF11 and other GDF11 pathway modulators for cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.

Product overview

Elevian is developing a pipeline of regenerative medicines centered on rGDF11 (recombinant Growth Differentiation Factor 11) and other GDF11 pathway modulators. The lead product rGDF11 is a recombinant protein therapeutic in preclinical/IND-enabling stages for stroke recovery, with potential applications across multiple age-related diseases. The company's therapeutic approach focuses on restoring youthful regenerative capacity by targeting the GDF11 pathway, which declines with age.

Differentiator

Problem solved

Functional benefit

Products and services

• rGDF11 (recombinant Growth Differentiation Factor 11) Recombinant protein therapeutic developed for treatment of stroke in the hours and days following the event; in preclinical animal models, has facilitated recovery of motor function in ischemic and hemorrhagic stroke by promoting neovascularization, stimulating neurogenesis, and reducing inflammation. Being advanced toward IND-enabling studies and Phase 1 clinical trials.
• GDF11 Pathway Modulators Pipeline of therapeutic programs utilizing rGDF11 and other modulators of the GDF11 pathway for the treatment of multiple aging-associated diseases including cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction. Targets improvements in glucose metabolism, insulin response, insulin sensitivity, weight loss, and tissue regeneration across multiple organ systems.

Quantifiable outcome

• rGDF11 improves limb and core body motor function measures (forelimb placement, hindlimb placement, and elevated body swing) in rat permanent MCAO model of ischemic stroke when dosing initiated within 24 hours or up to several days post stroke
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered strategic and core.

• Insilico MedicinestrategicTechnology or Integration · 9 January 2019Elevian entered a research collaboration with Insilico Medicine to discover drugs that target aging using state-of-the-art AI-enabled drug discovery techniques. The partnership leverages Insilico's AI platform to identify and develop GDF11 pathway modulators.
• Harvard Stem Cell InstitutecoreStrategic or Co-development PartnerElevian's research is sponsored at Harvard Stem Cell Institute laboratories, with scientific co-founders Lee Rubin, Amy Wagers, Rich Lee, and Ryan Walker leading research on rGDF11 pharmacokinetics, cardiovascular preclinical models, neurodegenerative models, and protein engineering.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Athersys: Clinical-stage cell therapy company developing MultiStem for ischemic stroke and other conditions — the closest direct competitor to Elevian in regenerative stroke therapy, with a similar late-preclinical/early-clinical profile.
• SanBio: Cell therapy company developing SB623 (modified allogeneic mesenchymal stem cells) for chronic stroke recovery — directly comparable regenerative medicine approach for the same post-stroke indication.
• ReNeuron: UK-based clinical-stage cell therapy company with a CTX stem cell line for stroke disability — directly comparable in indication and regenerative mechanism.
• Unity Biotechnology: Clinical-stage biotechnology company developing senolytic therapeutics to address aging-related diseases — directly comparable mission of treating age-driven degeneration, though with a small-molecule senolytic rather than a regenerative protein approach.
• Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplants for CNS and other indications — comparable regenerative medicine platform targeting central nervous system repair.
• BioTime (Lineage): Regenerative medicine company developing cell-based therapies across multiple age-related disease areas — directly comparable in regenerative medicine orientation, though now operating primarily through Lineage Cell Therapeutics.

Broad incumbents

• Mesoblast: Commercial-stage cell therapy company with mesenchymal stem cell platforms in inflammatory and cardiovascular diseases — broader incumbent with overlapping regenerative biology and relevant industry context (Elevian SVP Tony Sandrasagra was previously VP R&D there).
• Calico Life Sciences: Alphabet-backed R&D company focused on aging and age-related diseases — a well-funded, broadly positioned incumbent in the longevity/regenerative medicine space with overlapping scientific ambition.
• Altos Labs: Well-capitalized (>$3B raised) biotech focused on cellular reprogramming to reverse disease, injury, and age-related conditions — directly overlapping mission of restoring youthful regenerative capacity.

Emerging players

• Insilico Medicine: AI-driven drug discovery company focused on aging and age-related diseases — overlapping longevity mission and an existing Elevian research collaborator, providing pipeline expansion leverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ElevianInc
• Facebookfacebook.com/100057474068389
• LinkedInlinkedin.com/company/elevian-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles25 records

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elevian